脊柱液中的生物标记比率可以预测渐进的MS和对新疗法的反应。 A biomarker ratio in spinal fluid may predict progressive MS and response to new therapies.

多伦多大学牵头的一项研究发现,脑脊髓炎液体中CXCL13与BAFF蛋白质的比率很高,这可能表明浸泡器中存在分节炎症,这是渐进性多发性硬化症的一个关键因素。 A University of Toronto-led study has found that a high ratio of CXCL13 to BAFF proteins in cerebrospinal fluid may signal compartmentalized inflammation in the leptomeninges, a key factor in progressive multiple sclerosis. 鼠标模型和人体组织中确认的生物标志与更大的炎症有关,有助于确定最有可能对BTK抑制疗法作出反应的病人。 The biomarker, identified in both mouse models and human tissue, correlates with greater inflammation and could help identify patients most likely to respond to BTK inhibitor therapies. 研究人员建议使用这一比率来改进临床试验设计,并促成更早、有针对性的治疗。 Researchers suggest using the ratio to improve clinical trial design and enable earlier, targeted treatment. 该小组由Jen Gommerman和Valeria Ramaglia领导,目前正在探索其预测疾病发展的能力,并与制药公司合作。 The team, led by Jen Gommerman and Valeria Ramaglia, is now exploring its ability to predict disease progression and collaborating with pharmaceutical companies. 这项工作由加拿大和美国卫生机构资助。 The work was funded by Canadian and U.S. health agencies.